TB Assay for Nonhuman Primates Using Recombinant Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting tuberculosis (TB) in nonhuman primates, such as tuberculin skin testing (TST), are impractical, lack sensitivity and specificity, leading to frequent false positives and negatives, which complicates the management of TB in captive colonies and poses a public health risk.
Innovation Solution
A diagnostic method using defined mixtures of recombinant mycobacterial antigens in a lateral flow assay format that detects IgM and IgG antibodies, providing higher sensitivity and specificity, and is easier to administer, overcoming animal-to-animal variations in antigen recognition and reducing the need for invasive procedures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tuberculin skin testing (TST) is used to detect TB in nonhuman primates, then the test can identify TB exposure, but the test lacks sensitivity and produces frequent false negatives
Solution Approach 1:
The patent segments the single TST measurement into multiple independent serological measurements (IgM and IgG antibody detection) using different antigen preparations. This segmentation allows the test to capture TB exposure signals that TST misses, particularly in cases of anergy or early infection, thereby improving sensitivity and reducing false negatives
Solution Approach 2:
The patent changes the measurement parameter from skin reaction (TST) to serum antibody levels (serology). By detecting IgM and IgG antibodies against mycobacterial antigens in blood serum, the test bypasses the limitations of cell-mediated immunity that cause false negatives in TST, achieving higher sensitivity
2Reliability
If tuberculin skin testing (TST) is used to detect TB in nonhuman primates, then the test can identify TB exposure, but the test lacks specificity and produces frequent false positives
Solution Approach 1:
The patent segments the single specificity check into multiple independent serological assays using different antigen preparations (whole cell, sonicated, recombinant). This segmentation allows cross-validation of positive results, reducing false positives by requiring consistency across multiple antigen-specific antibody detections
Solution Approach 2:
The patent changes from detecting skin hypersensitivity (non-specific inflammatory response) to detecting specific IgM and IgG antibody isotypes against defined mycobacterial antigens. This parameter change enables differentiation between specific TB exposure and non-specific reactions, improving specificity
3Reliability
If tuberculin skin testing (TST) is performed on nonhuman primates, then TB exposure can be detected, but the procedure is impractical and requires deep chemical restraint or anesthesia
Solution Approach 1:
The patent extracts the detection function from the invasive skin testing procedure to a simple blood sampling procedure. By collecting serum through venipuncture or other minimally invasive methods and testing for antibodies in the laboratory, the test achieves the same detection capability without requiring deep restraint, anesthesia, or repeated handling
Solution Approach 2:
The patent replaces the mechanical skin injection and visual inspection system with a biochemical serological assay system. Antibody-antigen interactions in serum provide the detection mechanism, eliminating the need for intradermal injections, restraint apparatus, and repeated animal handling
4Reliability
If multiple tuberculin skin tests are performed to reduce false negatives, then sensitivity may improve, but the time and resources required increase significantly
Solution Approach 1:
The patent merges multiple detection capabilities (IgM detection, IgG detection, whole cell antigen response, sonicated antigen response, recombinant antigen response) into a single serological test platform. This allows comprehensive TB exposure assessment in one testing session rather than requiring multiple TST administrations over time
Solution Approach 2:
The patent performs preliminary detection of TB exposure through serology, which can identify infections that TST would miss in early stages. This preliminary action allows for earlier intervention and reduces the need for repeated testing to confirm infection status
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables early detection of TB, reduces false negatives and positives, and is more practical for use in nonhuman primate populations, improving the management and public health safety related to TB in these animals.
Implementation Method 1
A diagnostic method using defined mixtures of recombinant mycobacterial antigens in a lateral flow assay format that detects IgM and IgG antibodies
Data Source
AI summary
Systems, methods, and compositions for a diagnostic method for detecting TB in non-human primates that is easy to use, sensitive, and specific. The method utilizes recombinant mycobacterial antigens, such as polyfusion proteins. The method utilizes an antigen-antibody-antigen arrangement to detect TB infection in nonhuman primates. The method can detect IgM antibodies to TB, in addition to IgG antibodies, providing ability to detect TB earlier in nonhuman primate TB infection as compared to conventional TB tests.